BACKGROUND AND PURPOSE: No widespread clinical method provides specific information
about the angiogenic characteristics of gliomas. We characterized blood volume and …

Purpose We performed a phase II study to evaluate the combination of imatinib mesylate,
an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a …

Depending on dose, dexamethasone has been shown to inhibit or stimulate growth of rat 9L
gliosarcoma and decrease the expression of vascular endothelial growth factor (VEGF), an …

Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin
81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced …

Purpose Bevacizumab is an active anti-angiogenic agent in the treatment of recurrent
glioblastoma. Temozolomide can prolong survival in patients with newly diagnosed glioblastoma. …

… Badruddoja, MA, Sampson JH Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH,
Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess
efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid …

2058 Background: SL-701 is a novel immunotherapy comprised of synthetic peptides
designed to elicit an anti-tumor immune response against GBM targets: interleukin-13 receptor …

Purpose To assess the efficacy and toxicity of intraresection cavity iodine-131–labeled murine
antitenascin monoclonal antibody 81C6 ( 131 I-m81C6) among recurrent malignant brain …

Cloretazine (VNP40101M) is a newly synthesized alkylating agent belonging to a novel class
of alkylating agents called 1,2-bis(sulfonyl)hydrazines. Agents that belong to this class do …